Face the Future: Mary Kay’s AI Foundation Finder Poised to Disrupt the Beauty Game
14.8.2025 14:00:00 CEST | Business Wire | Press Release
Mary Kay Inc., a global leader in direct selling and skin innovation, announces the launch of its cutting-edge AI Foundation Finder – an intuitive technology designed to help consumers effortlessly find their foundation match, while empowering Mary Kay independent beauty consultants to guide their customers in finding the right match – right from their phones.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250814569267/en/
“The launch of our AI-powered Foundation Finder reflects a continued commitment to innovation in personalized beauty,” said James Whatley, Mary Kay’s Chief Information Officer. “By leveraging an exclusive AI technology in the Direct Selling channel, we’re able to provide shade recommendations in seconds, while making the consumer experience intuitive, inclusive, and enjoyable. Our Mary Kay independent beauty consultants will now have a powerful digital partner that elevates their business, enhances customer trust, and reimagines how beauty is delivered in a tech-enabled world.” (Photo Courtesy: Mary Kay Inc.)
A first in the direct selling industry, this AI Foundation Finder uses advanced artificial intelligence to scan a customer’s face on their mobile phone and provide personalized shade recommendations in just seconds. What sets this AI-powered tool apart is that it is informed by a scientifically developed scale offering an inclusive and nuanced understanding of human skin tones. The technology captures the user's skin tone using their camera and then matches it to the most accurate Mary Kay foundation shade by analyzing the user’s skin tone and the corresponding RGB values of the Mary Kay foundation products1. Mary Kay holds exclusive rights to the tool, making it a true direct selling industry disruptor2.
“AI Foundation Finder fuels our vision to be a beauty disruptor in the direct selling space and beyond,” said Dr. Lucy Gildea, Mary Kay’s Chief Brand and Scientific Officer. “We are pioneering AI shade matching globally, helping consumers meet their foundation match within the diverse range of foundation finishes in the Mary Kay® Flawless Face portfolio. Embracing beauty tech marks a unique opportunity to elevate the category and cultivate our next-generation beauty community.”
The AI Foundation Finder aligns with a rising demand for hyper personalized, tech-enabled beauty solutions amid broader cultural and technological shifts. As the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International for three consecutive years3 in 2023, 2024, and again in 2025, this launch further reflects Mary Kay’s commitment to digital innovation, inclusivity, and empowering our beauty entrepreneurs around the world.
“The launch of our AI-powered Foundation Finder reflects a continued commitment to innovation in personalized beauty,” said James Whatley, Mary Kay’s Chief Information Officer. “By leveraging an exclusive AI technology in the Direct Selling channel, we’re able to provide shade recommendations in seconds, while making the consumer experience intuitive, inclusive, and enjoyable. Our Mary Kay independent beauty consultants will now have a powerful digital partner that elevates their business, enhances customer trust, and reimagines how beauty is delivered in a tech-enabled world.”
The tool is now available in select markets and will be rolling out globally in the coming months. For more information, please visit here.
AI Foundation Finder Highlights:
- Beauty tech: The user’s camera captures real-time tracking of the user’s input video or images with precise detection of 151 facial feature points.
- Inclusiveness: The Mary Kay AI Foundation Finder is based on a proprietary 10-shade scale designed to accurately represent a wide range of human skin tones with inclusivity and precision in mind.
- Performance: In our consumer tests, 83% of consumers expressed that they would be likely to purchase their recommended match. In the Mary Kay Independent Beauty Consultant (IBC) tests, 100% of the Mary Kay IBCs said they would be very likely to use the tool in their business.
- Access: AI Foundation Finder is integrated into the online shopping experience, accessible from www.marykay.com or through the iCatalog, consumers can easily scan and instantaneously find their foundation match.
- Privacy: The AI Foundation Finder does not store or process biometric data.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X.
1 | RGB code stands for red, green, and blue code. It is a color model used in digital imaging and computer graphics to represent colors. Each color is represented by a combination of red, green, and blue values, typically ranging from 0 to 255. | |
2 | Mary Kay Inc. holds the exclusive rights to the tool for the first 12 months from launch. | |
3 | “Source Euromonitor International Limited; Beauty and Personal Care 2025 Edition, value sales at RSP, 2024 data” |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250814569267/en/
Contacts
Mary Kay Inc. Corporate Communications
marykay.com/newsroom -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fnewsroom.maryk
ay.com%2F&esheet=54308049&newsitemid=20250814569267&lan=en-US&anchor=marykay.com
%2Fnewsroom&index=12&md5=179c07b05c3bb793a659a730148e1fbb
972.687.5332 or media@mkcorp.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom